Drugs Market: Comprehensive Patent Search Analysis for Vemurafenib, Colesevelam, Rifaximin and more in New Market Research Report at ReportsnReports.com

Dallas, Texas (PRWEB) February 19, 2013

Used by the world’s leading generic pharmaceutical companies and legal teams, Pipeline Developer minimizes the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analyzed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information.

Pipeline Developer features:

•     Comprehensive patent searching, covering the world's key territories (see 'search coverage' below)
•     Identifies patents covering molecule, formulation, process, use, combination and assay techniques (see 'Patent Categories Identified ‘below)
•     Patent identification, categorization and interpretation
•     Grouped by patent family and assigned to development categories based on Interpretation of key aspects of the patent claims
•     Manual filtration of patents not relevant to generic development
•     Updated on a monthly basis, including changes to patent families, statuses, and litigation
•     Enables fast analysis and verification by hyper-linking to crucial patent documents and national registers

Patent Categories Identified:
1. Molecular Form
a) Molecule Patents
b) Salts, Hydrates & Solvates
c) Polymorphic Forms
d) Other Molecular Forms

2. Active Ingredient Preparation
a) Intermediates & Preparation Thereof
b) Final Synthetic Stages
c) Complete Synthesis
d) Purification Methods
e) Fermentation Methods
f) Biotechnology

3. Formulations & Methods Thereof
a) General Formulations & Methods
b) Injectable Formulations
c) Oral Formulations
d) Other Administration-Specific Formulations
e) Excipients, Kits & Packaging

4. Related Medical Use & Administration
a) New Use Related to Main Indication
b) Dosing Regimen/Administration Conditions
5. Active Ingredient Combinations
a) Novel Combinations
b) Use of Combinations
c) Dosing Regimen & Administration Conditions for Combinations

6. Analytical Methods
a) Assaying Methods
b) Methods of Determining Patient Suitability

Search coverage:
Clicking on a patent family displays detailed information on the 'Core' and 'Non-Core' 'Patent Family Equivalents'. 'Core Patent Family Equivalents' are equivalent patents from territories that are individually verified and monitored for changes, including British, German, Spanish, French, US, Canadian, Australian, European, and PCT patents. Statuses are also monitored and updated. 'Extended Patent Family Equivalents' are equivalent patents found through the INPADOC database, increasing the search coverage to 70 countries.

Patent and national register access:
Clicking on a listed patent/application number or text or image link will launch a pop-up window containing an image of the patent, enabling easy analysis of the patent documents. Clicking on a register link launches a pop-up window with the patent office register extract for that patent. This allows investigation into the examination status of a pending patent, opposition of a granted patent and/or payment of maintenance fees. Please note that no extra charges apply to accessing or downloading documents of any kind.

Litigation alerts:
Informing you of developments in court, litigation alerts can also be accessed by clicking on the litigation symbol next to the status, with links to judgments where available.

Browse Reports Individually:
Vemurafenib - Comprehensive patent search - The Pipeline Developer report covers Vemurafenib

•     Vemurafenib indications: Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma
•     Vemurafenib innovator: Roche (Zelboraf)

Colesevelam - Comprehensive patent search - The Pipeline Developer report covers Colesevelam

•     Colesevelam indications: Adjucntive therapy to diet for reducing elevated low-density lipoprotein cholesterol (LDL-C) or cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa), optionally in combination with a HMG-CoA reductase inhibitor; Adjunctive therapy to diet and exercise for improving glycemic control in patients with type 2 diabetes mellitus; Treatment of primary hypercholesterolaemia in combination with Ezetimibe, with or without a statin
•     Colesevelam innovator: Daiichi Sankyo (Welchol); Genzyme (Cholestagel); Valeant (Lodalis)

Rifaximin - Comprehensive patent search - The Pipeline Developer report covers Rifaximin

•     Rifaximin indications: Treatment of traveller's diarrhoea; Treatment of hepatic encephalopathy, optionally in combination with Lactulose
•     Rifaximin innovator: Norgine (Xifaxan, Xifaxanta); Salix (Xifaxan); Alfa Wassermann (Flonorm, Normix, Redactiv, Xifaxan); Formenti (Rifacol)

Nevirapine - Comprehensive patent search- The Pipeline Developer report covers Nevirapine

•     Nevirapine indications: Treatment of HIV-1 infection in combination with other antiretroviral agents, such as Lamivudine, Stavudine, Zidovudine and Tenofovir
•     Nevirapine innovator: Boehringer Ingelheim (Viramune, Viramune XR)

Liraglutide - Comprehensive patent search - The Pipeline Developer report covers Liraglutide

•     Liraglutide indications: Treatment of type 2 diabetes mellitus, optionally in combination with Metformin and/or a sulphonylurea
•     Liraglutide innovator: Novo Nordisk (Victoza)

Vilazodone - Comprehensive patent search - The Pipeline Developer report covers Vilazodone

•     Vilazodone indications: Treatment of major depressive disorder
•     Vilazodone innovator: Forest (Viibryd)

Browse other reports on Pharmaceuticals Market

About US:
ReportsnReports.com is an online market research reports library of 200,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

PDF Print